FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2030622042> ?p ?o ?g. }

• W2030622042 abstract "Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DCIntroduction: Anti-diabetic biguanide drugs, such as metformin, have been shown to have anti-tumorigenic effects by behaving as AMPK activators and mTOR inhibitors. Phenformin is another biguanide with anti-diabetic activity that was withdrawn from the market due to a risk of lactic acidosis that was higher than that seen with metformin. In vitro and in vivo studies suggest that phenformin may be more potent for inhibiting tumor growth than metformin. Thus, our objective was to assess the effect of phenformin on proliferation and apoptosis in ovarian cancer cell lines.Methods: Three ovarian cell lines, SKOV3, IGROV1, and HEY, were used. Cell proliferation was assessed by MTT assay after exposure to phenformin and after exposure to phenformin under varying glucose levels. Apoptosis was analyzed by Annexin V-FITC assay. Cell cycle progression was evaluated by Cellometer. Western immunoblotting was performed to determine expression of the downstream targets of phenformin, including AMPK, ribosomal protein S6, cyclin D and E2, cyclin dependent kinase (CDK) 4 and 6, p21 and p27. Inhibition of adhesion by phenformin was assessed by in vitro adhesion assay.Results: Phenformin potently inhibited proliferation in a dose-dependent manner in all three ovarian cancer cell lines (IC50 = 2.5mM for SKOV3 and HEY, 1mM for IGROV1 at 48 hours) (p = 0.0035 – 0.00001). Inhibition of proliferation was found at normal, low and high glucose concentrations, but greater potency was observed under low glucose concentrations. Treatment with phenformin resulted in G1 cell cycle arrest and induction of apoptosis. Cellular adhesion was decreased by 14-32% in the ovarian cancer cell lines at a phenformin dose of 2.5mM (p = 0.009 – 0.0001). Western immunoblot analysis demonstrated that phenformin induced phosphorylation of AMPK, its immediate downstream mediator, within 18 hours of exposure. In parallel, treatment with phenformin decreased phosphorylation of the S6 protein, a key target of the mTOR pathway. Phenformin was also found to increase the cell cycle inhibitors, p21 and p27, and decrease cyclin D, cyclin E2, CDK4 and CDK 6, corresponding with G1 arrest in these cell lines.Conclusion: Phenformin potently inhibited ovarian cancer cell growth via G1 arrest and increased apoptosis. Although the risk/benefit ratio clearly favors metformin over phenformin for the treatment of diabetes, this may not hold true for the treatment of cancer if phenformin were found to have superior anti-tumorigenic activity. Continued work is needed to explore the benefits of both metformin and phenformin for the treatment of ovarian cancer and the optimal therapeutic index.Citation Format: Amanda L. Jackson, Joshua E. Kilgore, Haifeng Qiu, Chunxiao Zhou, Paola A. Gehrig, Victoria L. Bae-Jump. Antitumorigenic effects of phenformin in human ovarian cancer cell lines. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 2442. doi:10.1158/1538-7445.AM2013-2442" @default.
• W2030622042 created "2016-06-24" @default.
• W2030622042 creator A5007925500 @default.
• W2030622042 creator A5063523041 @default.
• W2030622042 creator A5069321096 @default.
• W2030622042 creator A5070219310 @default.
• W2030622042 creator A5084844090 @default.
• W2030622042 creator A5088929176 @default.
• W2030622042 date "2013-04-15" @default.
• W2030622042 modified "2023-10-15" @default.
• W2030622042 title "Abstract 2442: Antitumorigenic effects of phenformin in human ovarian cancer cell lines." @default.
• W2030622042 doi "https://doi.org/10.1158/1538-7445.am2013-2442" @default.
• W2030622042 hasPublicationYear "2013" @default.
• W2030622042 type Work @default.
• W2030622042 sameAs 2030622042 @default.
• W2030622042 citedByCount "0" @default.
• W2030622042 crossrefType "proceedings-article" @default.
• W2030622042 hasAuthorship W2030622042A5007925500 @default.
• W2030622042 hasAuthorship W2030622042A5063523041 @default.
• W2030622042 hasAuthorship W2030622042A5069321096 @default.
• W2030622042 hasAuthorship W2030622042A5070219310 @default.
• W2030622042 hasAuthorship W2030622042A5084844090 @default.
• W2030622042 hasAuthorship W2030622042A5088929176 @default.
• W2030622042 hasConcept C126322002 @default.
• W2030622042 hasConcept C134018914 @default.
• W2030622042 hasConcept C184235292 @default.
• W2030622042 hasConcept C2777688063 @default.
• W2030622042 hasConcept C2778877718 @default.
• W2030622042 hasConcept C2780124434 @default.
• W2030622042 hasConcept C2780323712 @default.
• W2030622042 hasConcept C502942594 @default.
• W2030622042 hasConcept C55493867 @default.
• W2030622042 hasConcept C555293320 @default.
• W2030622042 hasConcept C62112901 @default.
• W2030622042 hasConcept C71924100 @default.
• W2030622042 hasConcept C86803240 @default.
• W2030622042 hasConcept C97029542 @default.
• W2030622042 hasConcept C98274493 @default.
• W2030622042 hasConceptScore W2030622042C126322002 @default.
• W2030622042 hasConceptScore W2030622042C134018914 @default.
• W2030622042 hasConceptScore W2030622042C184235292 @default.
• W2030622042 hasConceptScore W2030622042C2777688063 @default.
• W2030622042 hasConceptScore W2030622042C2778877718 @default.
• W2030622042 hasConceptScore W2030622042C2780124434 @default.
• W2030622042 hasConceptScore W2030622042C2780323712 @default.
• W2030622042 hasConceptScore W2030622042C502942594 @default.
• W2030622042 hasConceptScore W2030622042C55493867 @default.
• W2030622042 hasConceptScore W2030622042C555293320 @default.
• W2030622042 hasConceptScore W2030622042C62112901 @default.
• W2030622042 hasConceptScore W2030622042C71924100 @default.
• W2030622042 hasConceptScore W2030622042C86803240 @default.
• W2030622042 hasConceptScore W2030622042C97029542 @default.
• W2030622042 hasConceptScore W2030622042C98274493 @default.
• W2030622042 hasLocation W20306220421 @default.
• W2030622042 hasOpenAccess W2030622042 @default.
• W2030622042 hasPrimaryLocation W20306220421 @default.
• W2030622042 hasRelatedWork W1990063646 @default.
• W2030622042 hasRelatedWork W2005447769 @default.
• W2030622042 hasRelatedWork W2008540208 @default.
• W2030622042 hasRelatedWork W2046581895 @default.
• W2030622042 hasRelatedWork W2062091839 @default.
• W2030622042 hasRelatedWork W2074028608 @default.
• W2030622042 hasRelatedWork W2327834453 @default.
• W2030622042 hasRelatedWork W2328288936 @default.
• W2030622042 hasRelatedWork W2334347430 @default.
• W2030622042 hasRelatedWork W2478601601 @default.
• W2030622042 hasRelatedWork W2486934176 @default.
• W2030622042 hasRelatedWork W2490442601 @default.
• W2030622042 hasRelatedWork W2611906948 @default.
• W2030622042 hasRelatedWork W2762738400 @default.
• W2030622042 hasRelatedWork W2808511456 @default.
• W2030622042 hasRelatedWork W2930111576 @default.
• W2030622042 hasRelatedWork W2954337298 @default.
• W2030622042 hasRelatedWork W2963592446 @default.
• W2030622042 hasRelatedWork W3032750361 @default.
• W2030622042 hasRelatedWork W3189742732 @default.
• W2030622042 isParatext "false" @default.
• W2030622042 isRetracted "false" @default.
• W2030622042 magId "2030622042" @default.
• W2030622042 workType "article" @default.